A new study on psilocybin, the psychedelic compound found in “magic mushrooms,” is pushing the boundaries of what scientists think these substances might do inside the body. For years, psilocybin research has focused largely on mental health, particularly depression, addiction, end-of-life anxiety, and PTSD. But researchers at Emory University in Atlanta, Georgia, and Baylor College of Medicine in Houston, Texas, are now asking a much larger question: Could psychedelics influence the biology of aging itself?

“Ninety-nine percent of what we know about psilocybin is what it does in the brain, and clinical outcomes,” says lead author Dr. Louise Hecker, PhD, clinical associate professor at Baylor College of Medicine. “This is the first study to demonstrate its potent impacts on systemic aging.”

Their study, published in 2025 in the journal npg Aging, found that psilocin, the active metabolite produced when the body breaks down psilocybin, extended the lifespan of human cells in laboratory experiments and improved survival in older mice. These results are preliminary, and researchers caution that the work is still in its earliest stages. Yet the paper has ignited growing discussion among scientists studying longevity, cellular repair, and age-related disease. These findings raise a compelling possibility—that psychedelics may act not only on the brain but across the body’s aging systems.

In the lab, researchers exposed human lung and skin fibroblast cells to psilocin over an extended period. Compared with untreated cells, the psilocin-treated cells continued dividing longer before entering senescence, the state in which aging cells stop functioning normally. Some cells experienced lifespans more than 50 percent longer.

Hecker first got interested in psilocybin when a friend asked about it and she couldn’t answer. “I was intrigued by the fact that it was being used for so many different medical indications and also that one dose was reported to have positive impacts up to five years later,” says Hecker, “this was extremely interesting because it’s eliminated from the body within a day. How does it lead to long-term impacts?”

The study has started answering some of those questions, though some of the longer-term impacts are still unknown. And this research has produced more questions, which need to be investigated, says Hecker.

In response to concerns about increased cancer risks with continued cell division, she says, “our ongoing studies in the lab are looking at this, but it’s too early to know if cancer is a concern. This will take more funding and time to rigorously evaluate the potential for cancer risk.”

Treated cells in the study showed signs of healthier aging. Cells had reduced oxidative stress, lower levels of inflammatory and DNA-damage markers, and preserved telomere length. Telomeres are the protective caps at the ends of chromosomes that shorten as humans age. Shortened telomeres have been linked to chronic stress, depression, cardiovascular disease, and age-related decline.

The mouse findings in the study were even more provocative. Researchers administered psilocybin once a month to female mice that were already elderly, roughly equivalent to humans in their early 60s. After 10 months, 80 percent of the psilocybin-treated mice were still alive compared with only 50 percent of untreated mice. Researchers also observed visible differences in appearance, including improved fur quality and reduced whitening of hair.

However, this study stops far short of proving psilocybin extends lifespan in humans, because mouse studies frequently fail to translate into meaningful human outcomes. “People often want to extrapolate data from mice and directly apply it to themselves,” says Hecker, “[but] no one should do that when it comes to a drug that you are thinking about taking. I just tell people to be patient and keep your eye open to the new research studies and clinical trials that are emerging.”

The idea that psychedelics could impact the body’s aging machinery represents a major shift in how psilocybin is understood. Traditionally, psychedelics have been studied through a neurological lens, primarily for their effects on consciousness, mood, and perception. But serotonin receptors affected by psilocybin are distributed throughout the body, including in the immune system, cardiovascular tissue, skin, lungs, and blood vessels. Scientists increasingly suspect psychedelics may have broad systemic effects involving inflammation, oxidative stress, metabolism, and cellular repair.

The study also arrives at a moment when scientists are increasingly examining the relationship between mental health and biological aging. Chronic depression, anxiety, trauma, and stress have all been linked to accelerated aging markers, including inflammation and telomere shortening. Some researchers now wonder whether psilocybin’s profound psychological effects and potential cellular effects may ultimately be interconnected.

Still, researchers do not yet know whether psilocybin truly slows aging itself or simply improves the body’s ability to tolerate age-related stress. They also do not know whether the same effects would occur in humans, what dosing strategies might be safest, or whether long-term use could carry risks, including possible cancer concerns related to prolonged cellular survival.

“There are only a handful of studies that have looked at its systemic impacts,” explained Hecker, “this is in large part due to its schedule I designation. This creates regulatory challenges that make it very challenging to perform psilocybin research studies.” A schedule 1 designation means that the drug is not approved for medical use, even when dispensed by a doctor, and there’s a high potential for abuse and physical or psychological dependence.

The next phase of the research is a long-life study, funded by Vail Health Foundation, which will start enrolling healthy elderly patients in late 2026. “My role on the project at Baylor College of Medicine will be to evaluate the impact of psilocybin on biological aging, the primary endpoint, using clinical samples collected from patients enrolled in this trial,” shared Hecker. The trial will measure thousands of aging biomarkers, including telomere length, epigenetic, transcriptomic, proteomic, metabolomic, and microbiome profiling. Additionally, there will be lab studies to evaluate its therapeutic potential for age-associated diseases.

“This has blown open the door to an entirely new frontier for psychedelic research, as no prior studies have ever evaluated this,” says Hecker. She believes that if validated by human trials, it could be absolutely transformative for improving human health span and helping people to live healthier longer.

For decades, aging research has searched for interventions capable of influencing multiple systems at once: inflammation, stress responses, DNA repair, metabolism, and resilience. Psilocybin may not ultimately prove to be the breakthrough some hope for, but this study suggests psychedelics could belong in an arena few imagined they would enter—lengthening healthspan, and life itself.

d